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The report by Professor Phillips and Miss King [l] 
brings to our attention several aspects of the UK 
and the French standards for disk dffusion antibiotic 
susceptibihty tests which have converged during the 
years of development in the field. The authors con- 
clude that international standardization might be closer 
than ever in the sense that pragmatic consensus may 
now be attainable. An error in their report relating to 
media used in Sweden certainly does not contradict this 
important message. 
The error which I would like to point out refers 
to the statement: ‘unlike the Swedes, who use PDM 
Antibotic Sensitivity Medium (AB Biodisc), and ...’. 
This hegemony of one medmm was certainly true 
several years ago, but today the market in Sweden for 
disk difhsion media is also shared by Oxoid IsoSensitest 
medmm. Therefore, the media trend in Sweden is also 
towards a diversity worthy of the European tradition. 
In spite of this increased flexibility, the national 
reference body in Sweden, SRGA [2], has been able to 
provide guidelines for both methodological standard- 
ization and for interpretation of results [3,4]. The 
concept of species-related zone diameter interpretive 
breakpoints [3,5] is used throughout the country, giving 
improved accuracy of the disk diffusion test [3].  These 
guidelines are issued for the two growth media used in 
Sweden, PDM (AB Biodisc) and IsoSensitest (Oxoid 
Ltd) [4]. Quality control limits are similarly issued for 
both media [6]. All information about zone break- 
points and control limits is regularly updated by SRGA 
and available on the Internet, on the web address: 
http://www.ltkronoberg.se/ext/raf/raf. htm. 
As mentioned by Phillips and King, the two types 
of media are indeed very similar. When the Swedish 
interpretive zone breakpoints for the different bacterial 
groups on the two media are compared for the different 
antibiotics, this striking similarity is apparent. Most of 
the time the zone breakpoints are identical, sometimes 
they differ by 1 mm, and there are occasional Merences 
of greater magnitude. It is clear that manufacturers have 
come a long way in the standardization of the growth 
media used for disk diffusion antibiotic susceptibility 
tests. 
The report by Phdlips and Kmg also provide the 
information that the French as well as the UK standards 
advocate an inoculum size which is 100-fold lighter 
than the inoculum according to NCCLS recommen- 
dations [l]. I would like to add that, also in Sweden (as 
well as in most other Scandinavian countries), the 
lighter inoculum is the recommended standard, giving 
several advantages over the NCCLS inoculum [4]. 
This common practice might further fachtate a future 
European consensus. 
Goran Kronvall 
Division of Clinical Microbiology, 
Karolinska Institute and Hospitals, 
Stockholm, Sweden 
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